Business Wire

Adtran launches Oscilloquartz SFP grandmaster clock for precise edge timing in 10G networks

9.9.2025 14:00:00 CEST | Business Wire | Press Release

Share

Adtran today launched the OSA 5401XG SyncPlug™, an SFP-based grandmaster clock that delivers precise PTP and NTP synchronization for 10Gbit/s edge and access networks. The new Oscilloquartz device enables timing distribution through a compact, plug-in form factor that requires no rack space or complex installation, empowering network operators to extend synchronization into space- and power-limited deployments. With multi-band GNSS support, compliance with PRTC‑B and compatibility with 10Gbit/s-only host platforms, it offers an efficient way to upgrade timing capabilities across sectors, including telecom, energy, defense, enterprise and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909324407/en/

Adtran’s new OSA 5401XG SyncPlug™ integrates seamlessly into existing infrastructure, delivering precise synchronization wherever it’s needed.

“As networks evolve, precise timing has to reach further, faster and into more constrained environments. That’s exactly what the 5401XG SyncPlug™ is built for. It’s a no-compromise solution that fits directly into existing infrastructure, requires almost no space or power and delivers the performance needed for next-generation services,” said Gil Biran, GM of Oscilloquartz, Adtran. “By integrating advanced GNSS capabilities in a 10Gbit/s-ready SFP module, we’re giving our customers an easier, smarter way to deploy resilient timing, whether modernizing legacy sites, extending coverage at the edge or rolling out new, timing-critical applications.”

The OSA 5401XG SyncPlug™ is a fully featured SFP-based synchronization device that supports PTP grandmaster, boundary and slave clock modes, Stratum 1 NTP server functionality, and SyncE for frequency synchronization. It plugs directly into standard 1Gbit/s or 10Gbit/s ports and consumes less than 2.5W, making it ideal for space- and power-sensitive locations. With multi-band GNSS (L1 and L5), the device enables compliance with enhanced timing standards such as PRTC-B and supports regional systems, including India’s IRNSS. It also offers advanced spoofing and jamming detection, extended holdover and up to 500,000 NTP transactions per second, ensuring performance and security at scale.

“Demand for precise synchronization is growing rapidly across edge and access networks, and it has to be delivered with minimal footprint and maximum resilience,” commented Igal Pinhasov, VP of product line management at Oscilloquartz, Adtran. “From mobile backhaul and energy grids to secure government and business networks, the OSA 5401XG SyncPlug™ fits directly into existing infrastructure to deliver full grandmaster functionality over 10Gbit/s. There’s no need for extra cabling, appliances or rack space. It’s an ideal solution for operators looking to modernize timing in challenging environments while simplifying deployment and strengthening performance.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250909324407/en/

Contacts

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Peter Schuman
+1 256 963 6305
investor.relations@adtran.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye